ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting

2024-04-24

ASCO会议免疫疗法临床结果临床2期临床1期

SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the acceptance of two abstracts for poster presentation at the American Society of Cancer Oncology (“ASCO”), which will be held in Chicago from May 31-June 4, 2024.

Session titles and information for the two abstracts are listed below and are now available on the ASCO online program planner.

Evorpacept plus enfortumab vedotin in patients with locally advanced or metastatic urothelial carcinoma: Phase 1a dose escalation results

Session Type and Title: Poster Presentation – Genitourinary Cancer – Kidney and Bladder

Session Date and Time: Sunday, June 2, 2024, 9:00 AM – 12:00 PM CDT

Location: Hall A

Abstract Number: 4575

ALX Oncology Sponsored Clinical Trial

Results of a Phase 2 study of evorpacept (ALX148), and cetuximab, and pembrolizumab in patients with refractory microsatellite stable metastatic colorectal cancer

Session Type and Title: Poster Presentation – Gastrointestinal Cancer – Colorectal and Anal

Session Date and Time: Saturday, June 1, 2024, 1:30 PM – 4:30 PM CDT

Location: Hall A

Abstract Number: 3530

Investigator-Sponsored Trial at the University of Colorado Cancer Center Cancer Center

Copies of the presentations will be available on the Publications section of ALX Oncology’s website following presentation at the meeting.

About ALX Oncology

ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 immune checkpoint inhibitor and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, evorpacept, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. To date, evorpacept has been dosed in over 500 subjects and has demonstrated promising activity and favorable tolerability profile across a range of hematologic and solid malignancies in combination with various leading anti-cancer antibodies. ALX Oncology is currently focusing on combining evorpacept with anti-cancer antibodies, antibody-drug conjugates (“ADCs”), and PD-1/PD-L1 immune checkpoint inhibitors.

Investor and Media Contact:

Caitlyn Doherty

Manager, Investor Relations and Corporate Communications, ALX Oncology

cdoherty@alxoncology.com

(650) 466-7125

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构